FDA Approves Penpulimab for Nasopharyngeal Cancer

The US Food and Drug Administration (FDA) has approved penpulimab-kcqx (Akeso Biopharma) in combination with cisplatin or carboplatin and gemcitabine as first-line treatment for adults with certain types of nasopharyngeal carcinoma (NPC), and as a single agent for certain patients with NPC disease progression on or after other treatments…